文献速递白血病造血干细胞移植与细胞治疗

FAB分类对首次完全缓解期接受异基因干细胞移植的急性髓系白血病非特指型患者预后预测的影响:欧洲血液与骨髓移植学会急性白血病工作组1690例患者分析

Impact of FAB classification on predicting outcome in acute myeloid leukemia, not otherwise specified, patients undergoing allogeneic stem cell transplantation in CR1: An analysis of 1690 patients from the acute leukemia working party of EBMT.
PubMed 文献 · Am J Hematol · 2017-02-07

基于欧洲血液与骨髓移植学会登记库,分析1690例在首次完全缓解期接受异基因干细胞移植的急性髓系白血病非特指型患者,评估FAB分类是否提供额外预后价值。多因素分析显示M6/M7患者无白血病生存期降低(HR 1.41,95%CI 1.01-1.99;P=.046)且非复发死亡率升高(HR 1.79,95%CI 1.06-3.01;P=.028)。在NPM1野生型队列中M6/M7与非复发死亡率升高相关(HR 2.17,95%CI 1.14-4.16;P=.019),FLT3-ITD阳性患者中特定FAB类型与不良结局紧密相关。结论认为FAB分类可能预测移植后结局。

要点

  • M6/M7患者较其他FAB类型无白血病生存期降低(HR 1.41,95%CI 1.01-1.99;P=.046)。
  • M6/M7患者非复发死亡率升高(HR 1.79,95%CI 1.06-3.01;P=.028)。
  • NPM1野生型中M6/M7与非复发死亡率升高相关(HR 2.17,95%CI 1.14-4.16;P=.019)。

核心结论

  • FAB分类可能预测急性髓系白血病非特指型患者移植后的结局。

研究设计与样本

  • 利用欧洲血液与骨髓移植学会登记库,分析1690例在首次完全缓解期接受异基因干细胞移植的急性髓系白血病患者,以确定FAB分类是否提供额外预后价值。

主要发现

  • 多因素分析显示,与其他FAB类型相比,M6/M7患者无白血病生存期降低(HR 1.41,95%CI 1.01-1.99;P=.046)。
  • M6/M7患者较其他FAB类型非复发死亡率升高(HR 1.79,95%CI 1.06-3.01;P=.028)。
  • 在NPM1野生型急性髓系白血病非特指型队列中,FAB M6/M7与非复发死亡率升高相关(HR 2.17,95%CI 1.14-4.16;P=.019)。
  • 在FLT3-ITD阳性患者中,多因素分析显示特定FAB类型与不良结局紧密相关。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The French, American, and British (FAB) classification system for acute myeloid leukemia (AML) is extensively used and is incorporated into the AML, not otherwise specified (NOS) category in the 2016 WHO edition of myeloid neoplasm classification. While recent data proposes that FAB classification does not provide additional prognostic information for patients for whom NPM1 status is available, it is unknown whether FAB still retains a current prognostic role in predicting outcome of AML patients undergoing allogeneic stem cell transplantation. Using the European Society of Blood and Bone Marrow Transplantation registry we analyzed outcome of 1690 patients transplanted in CR1 to determine if FAB classification provides additional prognostic value. Multivariate analysis revealed that M6/M7 patients had decreased leukemia free survival (hazard ratio (HR) of 1.41, 95% confidence interval (CI), 1.01-1.99; P = .046) in addition to increased nonrelapse mortality (NRM) rates (HR, 1.79; 95% CI, 1.06-3.01; P = .028) compared with other FAB types. In the NPM1wt AML, NOS cohort, FAB M6/M7 was also associated with increased NRM (HR, 2.17; 95% CI, 1.14-4.16; P = .019). Finally, in FLT3-ITD+ patients, multivariate analyses revealed that specific FAB types were tightly associated with adverse outcome. In conclusion, FAB classification may predict outcome following transplantation in AML, NOS patients.

来源:Am J Hematol,查看原文。版权归原作者所有。

引用

  1. Canaani J, Beohou E, Labopin M, et al. Impact of FAB classification on predicting outcome in acute myeloid leukemia, not otherwise specified, patients undergoing allogeneic stem cell transplantation in CR1: An analysis of 1690 patients from the acute leukemia working party of EBMT. Am J Hematol. 2017. PMID: 28052366. doi:10.1002/ajh.24640

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。